相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort
Luc de Saint-Martin et al.
AIDS (2010)
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
Kathleen E. Squires et al.
AIDS (2010)
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
Jose R. Arribas et al.
AIDS (2010)
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen
Jade Ghosn et al.
ANTIVIRAL THERAPY (2010)
Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study
R. Giuntini et al.
HIV MEDICINE (2010)
Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials
Dianne Carey et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition
F. Josephson
JOURNAL OF INTERNAL MEDICINE (2010)
Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients
D. R (Niel) Malan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Tenofovir Coadministration Is Not Associated With Lower Unboosted Atazanavir Plasma Exposure in the Clinical Setting
Andrea Caleagno et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Improvement in Lipid Profiles in Antiretroviral-Experienced HIV-Positive Patients With Hyperlipidemia After a Switch to Unboosted Atazanavir
Michael Sension et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial
Vincent Soriano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers
Grace A. Lee et al.
AIDS (2007)
Urolithiasis in HIV-positive patients treated with atazanavir
Carine Couzigou et al.
CLINICAL INFECTIOUS DISEASES (2007)
Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring
Judianne Slish et al.
THERAPEUTIC DRUG MONITORING (2007)
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN study (AI424-097) 48-week results
Jose Gatell et al.
CLINICAL INFECTIOUS DISEASES (2007)
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C
Pablo Barreiro et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort
P Braitstein et al.
AIDS (2006)
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients
AM Taburet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
The mechanism of insulin resistance caused by HIV protease inhibitor therapy
H Murata et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
